Date: 21 Apr 2011
Intensive glucose control and risk of cancer in patients with type 2 diabetes
Type 2 diabetes has been associated with an increased risk of cancer. This study examines the effect of more vs less intensive glucose control on the risk of cancer in patients with type 2 diabetes.
All 11,140 participants from the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) trial (ClinicalTrials.gov NCT00145925) were studied. Cancer incidence and cancer mortality was compared in groups randomised to intensive or standard glucose control. Information on events during follow-up was obtained from serious adverse event reports and death certificates. HRs (95% CI) were calculated for all cancers, all solid cancers, cancer deaths and site-specific cancers.
After a median follow-up of 5 years, 363 and 337 cancer events were reported in the intensive and standard control groups, respectively (incidence 1.39/100 person-years [PY] and 1.28/100 PY; HR 1.08 [95% CI 0.93–1.26]). The incidences of all solid cancers and cancer deaths were 1.25/100 PY and 0.15/100 PY in the intensive group and 1.15/100 PY and 0.13/100 PY in the standard group (HR 1.09 [95% CI 0.93–1.27] for solid cancers, and 1.17 [0.75–1.84] for cancer death). Across all the major organ systems studied, no significant differences in the cancer incidences were observed in the intensive and standard control groups.
More intensive glucose control achieved with a regimen that included greater use of gliclazide, insulin, metformin and other agents, did not affect the risk of cancer events or death in patients with type 2 diabetes.
Lam EK, Batty GD, Huxley RR et al (2010) Associations of diabetes mellitus with site-specific cancer mortality in the Asia-Pacific region. Ann Oncol. doi:10.1093/annonc/mdq1405
Saydah SH, Platz EA, Rifai N, Pollak MN, Brancati FL, Helzlsouer KJ (2003) Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 12:412–418PubMed
The ADVANCE Collaborative Group (2001) Study rationale and design of ADVANCE: action in diabetes and vascular disease—preterax and diamicron MR controlled evaluation. Diabetologia 44:1118–1120CrossRef
Okumura M, Yamamoto M, Sakuma H et al (2002) Leptin and high glucose stimulate cell proliferation in MCF-7 human breast cancer cells: reciprocal involvement of PKC-alpha and PPAR expression. Biochim Biophys Acta 1592:107–116PubMed
UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853CrossRef
- Intensive glucose control and risk of cancer in patients with type 2 diabetes
Volume 54, Issue 7 , pp 1608-1614
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Type 2 diabetes
- Glucose control
- Industry Sectors
- Author Affiliations
- 1. Julius Centre for Health Sciences and Primary Care, University Medical Centre (UMC), Utrecht, the Netherlands
- 2. Division of Pharmacoepidemiology and Pharmacotherapy, Institute for Pharmaceutical Sciences, Utrecht, the Netherlands
- 3. The George Institute for Global Health, University of Sydney, PO Box M201, Missenden Road, Sydney, NSW, 2050, Australia
- 4. School of Public Health, Monash University, Melbourne, VIC, Australia